Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?
Abstract Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-08-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13046-019-1362-1 |
| _version_ | 1818048608989085696 |
|---|---|
| author | Fengzhi Li Ieman Aljahdali Xiang Ling |
| author_facet | Fengzhi Li Ieman Aljahdali Xiang Ling |
| author_sort | Fengzhi Li |
| collection | DOAJ |
| description | Abstract Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into survivin’s functional role in cancers, thus providing promise for survivin as a cancer therapeutic target. Despite this, moving survivin-targeting agents into and through the clinic remains a challenge. In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin. In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy. We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy. |
| first_indexed | 2024-12-10T10:24:24Z |
| format | Article |
| id | doaj.art-74c8cdaf9be84cf2ac90917f712791a5 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-12-10T10:24:24Z |
| publishDate | 2019-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-74c8cdaf9be84cf2ac90917f712791a52022-12-22T01:52:46ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662019-08-0138112210.1186/s13046-019-1362-1Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?Fengzhi Li0Ieman Aljahdali1Xiang Ling2Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer CenterDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer CenterDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer CenterAbstract Survivin (also named BIRC5) is a well-known cancer therapeutic target. Since its discovery more than two decades ago, the use of survivin as a target for cancer therapeutics has remained a central goal of survivin studies in the cancer field. Many studies have provided intriguing insight into survivin’s functional role in cancers, thus providing promise for survivin as a cancer therapeutic target. Despite this, moving survivin-targeting agents into and through the clinic remains a challenge. In order to address this challenge, we may need to rethink current strategies in order to develop a new mindset for targeting survivin. In this Review, we will first summarize the current survivin mechanistic studies, and then review the status of survivin cancer therapeutics, which is classified into five categories: (i) survivin-partner protein interaction inhibitors, (ii) survivin homodimerization inhibitors, (iii) survivin gene transcription inhibitors, (iv) survivin mRNA inhibitors and (v) survivin immunotherapy. We will then provide our opinions on cancer therapeutics using survivin as a target, with the goal of stimulating discussion that might facilitate translational research for discovering improved strategies and/or more effective anticancer agents that target survivin for cancer therapy.http://link.springer.com/article/10.1186/s13046-019-1362-1Survivin cancer therapeuticssurvivinBIRC5Mcl-1XIAPcIAP2 |
| spellingShingle | Fengzhi Li Ieman Aljahdali Xiang Ling Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? Journal of Experimental & Clinical Cancer Research Survivin cancer therapeutics survivin BIRC5 Mcl-1 XIAP cIAP2 |
| title | Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? |
| title_full | Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? |
| title_fullStr | Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? |
| title_full_unstemmed | Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? |
| title_short | Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? |
| title_sort | cancer therapeutics using survivin birc5 as a target what can we do after over two decades of study |
| topic | Survivin cancer therapeutics survivin BIRC5 Mcl-1 XIAP cIAP2 |
| url | http://link.springer.com/article/10.1186/s13046-019-1362-1 |
| work_keys_str_mv | AT fengzhili cancertherapeuticsusingsurvivinbirc5asatargetwhatcanwedoafterovertwodecadesofstudy AT iemanaljahdali cancertherapeuticsusingsurvivinbirc5asatargetwhatcanwedoafterovertwodecadesofstudy AT xiangling cancertherapeuticsusingsurvivinbirc5asatargetwhatcanwedoafterovertwodecadesofstudy |